Loading...
ALLO Allogene Therapeutics Inc
Loading...
News
Allogene Therapeutics, Inc. The abnormal movement in the intraday session was rapidly pulled up by 5.05% near midday.
At 23:38 on October 26th, Beijing time, Allogene Therapeutics, Inc. (ALLO.us) shares changed, and the stock price rose 5.05% rapidly. As of press time, the stock was trading at US $16.44 per share, with a turnover of 457171 shares, a turnover rate of 0.32% and an amplitude of 4.66%. The most recent results show that the stock achieved operating income of $44000.00, net profit of-70.94 million US dollars, earnings per share of-0.53 US dollars and gross profit of-8.99 times earnings. Agency rating party
Allogene Therapeutics, Inc. Intraday movements rose sharply by 5.08% to $16.54.
At 23:02 on October 20, 2021, Beijing time, Allogene Therapeutics, Inc. (ALLO.us) shares fluctuated, and the share price rose sharply by 5.08%. As of press time, the stock was trading at US $16.54 per share, with a turnover of 564776 shares, a turnover rate of 0.40% and an amplitude of 5.21%. The most recent results show that the stock achieved operating income of $44000.00, net profit of-70.94 million US dollars, earnings per share of-0.53 US dollars, gross margin and price-to-earnings ratio of 9.03 times. Agency rating party
Allogene Therapeutics, Inc. Intraday movements rose 5.12 percent to $16.76 in morning trading.
At 21:32 on October 14, 2021, Allogene Therapeutics, Inc. (ALLO.us) shares fluctuated, rising 5.12%. As of press time, the stock was trading at US $16.76 per share, with a turnover of 269210 shares, a turnover rate of 0.19% and an amplitude of 3.58%. The most recent results show that the stock achieved operating income of $44000.00, net profit of-70.94 million US dollars, earnings per share of-0.53 US dollars, gross profit, price-to-earnings ratio of 9.16 times. In terms of agency rating
As CRISPR continues to falter, other CAR-T names aren't impacted
Although shares of CRISPR Therapeutics (CRSP -6.4%) have fallen since yesterday's after-the-bell announcement, its gene editing peers have not been impacted. Those results were from the company's ear
Allogene Therapeutics, Inc. Intraday movements rose sharply by 5.14%.
At 22:50 on October 13, 2021, Beijing time, Allogene Therapeutics, Inc. (ALLO.us) shares fluctuated, and the stock price soared by 5.14%. As of press time, the stock was trading at US $14.12 per share, with a turnover of 1.12772 million shares, a turnover rate of 0.79% and an amplitude of 5.55%. The most recent results show that the stock achieved operating income of $44000.00, net profit of-70.94 million US dollars, earnings per share of-0.53 US dollars, gross profit, price-to-earnings ratio of 7.72 times. Agency rating party
Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling. -- Barrons.com
By Jack Denton Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors. That is ba
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 1 0 0 Last 30
Allogene Therapeutics Is Maintained at Market Outperform by JMP Securities
DJ Allogene Therapeutics Is Maintained at Market Outperform by JMP Securities Ratings actions from Benzinga: https://www.benzinga.com/stock/ALLO/ratings (END) Dow Jones Newswires October 12,
Allogene Therapeutics analyst ratings
DateResearch FirmActionCurrentPT 10/12/21JMP SecuritiesMaintainsMarket Outperform27.0 10/08/21StifelDowngradesHold 10/08/21RBC CapitalMaintainsOutperform45.0 10/08/21Goldman SachsDowngradesNeutral20.0
Xenon Pharma, ChemoCentryx lead weekly healthcare gainers; Prelude, Allogene trail
While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector beca